Achaogen takes in $5.6M to fight bacterial infections

Pharmaceutical company Achaogen received a $5.6 million grant from the U.K.-based Wellcome Trust as part of its Seeding Drug Discovery Initiative. The money will go toward phase one clinical trials of the San Francisco company’s lead drug candidates, aimed at treating bacterial infections that are already resistent to multiple antibiotics.

It last raised funds in 2006, bringing in $26 million in second-round funding from Venrock, Versant Ventures, Domain Associates and Arch Venture Partners.

Next Story: Fark.com goes mainstream with Jeopardy appearance
Previous Story: Gene Security Network strings together $6M for in-vitro tech